Thus, each drug is an exceptional monopoly because each one will be indicated sooner or later during case study solution process a patient’s disease. As in any monopoly, drugs that extend case study answer survival of patients with incurable malignancies, even by a few weeks, can, hence, be priced at something price case study answer market will bear. Although case study solution same situation may occur in other chronic incurable illnesses, case study solution magnitude of case study answer problem is amplified in malignancies because case study solution impact and seriousness of a cancer diagnosis ends up in bigger willingness on case study answer part of patients and physicians to take on case study answer high costs of remedy. This is evidenced by case study answer elasticities percent change in use associated with a 1% augment in useful coinsurance rates of distinctiveness drug use by sufferers among 4 situations: rheumatoid arthritis, kidney disease, numerous sclerosis, and cancer. For example, Goldman et al19 said that if an insurance plan were to double case study answer cost of sharing for rheumatoid arthritis area of expertise drugs, overall spending on these drugs would lower by 21%. However, for cancer drugs, spending would be decreased by only 1%.